已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

医学 中止 内科学 临床终点 不利影响 实体瘤疗效评价标准 临床研究阶段 黑色素瘤 无进展生存期 肿瘤科 化疗 外科 胃肠病学 临床试验 癌症研究
作者
Chuanliang Cui,Yu Chen,Zhiguo Luo,Zhengyun Zou,Yu Jiang,Hongming Pan,Qingxia Fan,Jianfu Zhao,Qing Xu,Renbing Jiang,Xuan Wang,Taiyang Ma,Zhen Guo,Lu Si,Zhihong Chi,Xinan Sheng,Yiwei Dou,Qian Tan,Di Wu,Jun Guo
出处
期刊:BMC Cancer [BioMed Central]
卷期号:23 (1) 被引量:8
标识
DOI:10.1186/s12885-022-10473-y
摘要

Abstract Background Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands PD-L1 and PD-L2. Methods In this phase 2 trial, patients with locally advanced or metastatic melanoma who had failed conventional treatment (chemotherapy, targeted therapy, interferon, IL-2, et al.) were recruited. The patients were administrated with Pucotenlimab of 3 mg/kg every 3 weeks until disease progression, intolerable toxicity, or treatment discontinuation for any other reasons. The primary endpoint was the overall response rate (ORR). The secondary endpoints were disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and toxicity. Results One-hundred and nineteen patients were enrolled and followed up for 19.32 (ranging from 15.901 to 24.608) months by the cutoff date of July 30 th , 2021. The ORR was 20.17% (24/119, 95% CI, 13.370%-28.506%) based on both independent review committee (IRC) and the investigator’s assessment per RECIST v1.1. The median PFS were 2.89 (95% CI, 2.037–4.074) months and 2.46 (95% CI, 2.004–4.008) months based on IRC and investigator’s assessment, respectively, per RECIST v1.1. The median OS was 16.59 (95% CI, 13.963–26.973) months. Treatment-related adverse events (TRAEs) occurred in 77.3% (92/119) of the patients. The incidence of Grade ≥ 3 TRAEs was 15.1% (18/119). In addition, none of the patients died because of TRAEs. As for biomarker analysis, Eotaxin (CCL11) and MCP-1 (CCL2) were related to treatment response, while TNF-α and VEGF were related to treatment failure. Conclusions Pucotenlimab as a ≥ 2 nd line therapy showed promising efficacy and tolerable toxicity for patients with locally advanced or metastatic melanoma. Trial registration Clinicaltrials.gov Identifier: NCT04749485 (registered retrospectively on 11/02/2021).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Akim应助科研通管家采纳,获得10
1秒前
科研通AI2S应助科研通管家采纳,获得10
1秒前
1秒前
我是老大应助科研通管家采纳,获得10
2秒前
英俊的铭应助科研通管家采纳,获得10
2秒前
情怀应助科研通管家采纳,获得30
2秒前
2秒前
4秒前
大模型应助干净又晴采纳,获得10
4秒前
mellow发布了新的文献求助10
4秒前
YCG完成签到 ,获得积分10
4秒前
Amon发布了新的文献求助10
5秒前
称心嫣娆发布了新的文献求助10
6秒前
爆米花应助淡定采纳,获得10
7秒前
洞两完成签到,获得积分10
9秒前
10秒前
Akim应助俏皮的白柏采纳,获得10
10秒前
10秒前
13秒前
bkagyin应助一颗椰子糖耶采纳,获得10
15秒前
天天快乐应助露露采纳,获得10
15秒前
干净又晴发布了新的文献求助10
16秒前
17秒前
17秒前
wkjfh应助Leoniko采纳,获得10
18秒前
帅男发布了新的文献求助10
19秒前
wyp发布了新的文献求助10
20秒前
21秒前
子非鱼发布了新的文献求助10
21秒前
23秒前
阿氏之光发布了新的文献求助10
26秒前
烟花应助自由的读书人采纳,获得10
26秒前
酷炫抽屉完成签到 ,获得积分10
26秒前
27秒前
露露发布了新的文献求助10
27秒前
congenialboy发布了新的文献求助10
28秒前
29秒前
32秒前
33秒前
33秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989797
求助须知:如何正确求助?哪些是违规求助? 3531914
关于积分的说明 11255516
捐赠科研通 3270597
什么是DOI,文献DOI怎么找? 1805008
邀请新用户注册赠送积分活动 882181
科研通“疑难数据库(出版商)”最低求助积分说明 809190